CSL Of Australia, Talecris Of U.S. Warned By FDA Over Plasma Promos
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL has been accused, along with U.S.-based Talecris, of making misleading claims in competing promotion campaigns for blood products